- Home
- SKIN vs NMRA Comparison
SKIN vs NMRA Comparison
Compare SKIN & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIN
- NMRA
- Stock Information
- Founded
- SKIN 1997
- NMRA 2019
- Country
- SKIN United States
- NMRA United States
- Employees
- SKIN N/A
- NMRA N/A
- Industry
- SKIN Package Goods/Cosmetics
- NMRA
- Sector
- SKIN Consumer Discretionary
- NMRA
- Exchange
- SKIN Nasdaq
- NMRA Nasdaq
- Market Cap
- SKIN 295.5M
- NMRA 268.5M
- IPO Year
- SKIN N/A
- NMRA 2023
- Fundamental
- Price
- SKIN $2.53
- NMRA $1.62
- Analyst Decision
- SKIN Hold
- NMRA Buy
- Analyst Count
- SKIN 1
- NMRA 8
- Target Price
- SKIN $1.25
- NMRA $7.14
- AVG Volume (30 Days)
- SKIN 895.2K
- NMRA 383.3K
- Earning Date
- SKIN 11-11-2025
- NMRA 11-11-2025
- Dividend Yield
- SKIN N/A
- NMRA N/A
- EPS Growth
- SKIN N/A
- NMRA N/A
- EPS
- SKIN N/A
- NMRA N/A
- Revenue
- SKIN $310,064,000.00
- NMRA N/A
- Revenue This Year
- SKIN N/A
- NMRA N/A
- Revenue Next Year
- SKIN $6.05
- NMRA N/A
- P/E Ratio
- SKIN N/A
- NMRA N/A
- Revenue Growth
- SKIN N/A
- NMRA N/A
- 52 Week Low
- SKIN $0.78
- NMRA $0.61
- 52 Week High
- SKIN $2.56
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- SKIN 67.00
- NMRA 47.71
- Support Level
- SKIN $2.22
- NMRA $1.60
- Resistance Level
- SKIN $2.51
- NMRA $1.70
- Average True Range (ATR)
- SKIN 0.15
- NMRA 0.09
- MACD
- SKIN 0.04
- NMRA -0.01
- Stochastic Oscillator
- SKIN 95.16
- NMRA 8.51
About SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.